Neuro-Ophthalmology · Patient Guide
One eye dims.
It hurts to look sideways.
The problem is the nerve, not the eye.
Optic neuritis is inflammation of the optic nerve — the cable between eye and brain. It strips the insulation from nerve fibres, blurs and greys out vision over days, and for many people is the first sign of multiple sclerosis. Here is how it is recognised, what the landmark steroid trial actually found, and which features mean it is not the typical kind.
(ONTT)
overall (ONTT)
range
Section 01 — What It Is
The eye is healthy.
The cable behind it
is inflamed.
A patient with optic neuritis often has an eye that looks completely normal from the front — and, in most cases, a normal-looking optic disc too. The trouble is further back, in the retrobulbar optic nerve, where roughly a million nerve fibres carry the image from retina to brain.
In typical optic neuritis the immune system attacks the myelin sheath that insulates those fibres. Demyelinated fibres conduct signals slowly or not at all, so vision in the affected eye blurs, dims and loses colour over a few days, often reaching its worst within about one to two weeks. The same demyelinating process is what defines multiple sclerosis (MS), which is why the two are so closely linked.
Optic neuritis is inflammation of the optic nerve, usually in one eye, usually in adults aged about 20 to 45, and more often in women. It causes blurred or dim central vision developing over days, faded colours, and pain when the eye moves. Most typical cases start recovering within a few weeks without treatment. High-dose intravenous steroids speed recovery but do not change final vision. The brain MRI at presentation is the best predictor of future multiple sclerosis. Severe loss, both eyes, no pain, marked disc swelling or no recovery by about three weeks suggest an atypical cause — including NMOSD or MOG antibody disease — that needs urgent, different treatment.
Section 02 — Interactive
What the brain MRI
tells you about the next 15 years.
The Optic Neuritis Treatment Trial followed its patients for 15 years. The single strongest predictor of who went on to develop MS was whether the brain MRI at the first attack already showed white-matter lesions. Switch between the groups below.
The numbers are stark. Among ONTT patients whose baseline brain MRI showed no lesions, about 25% developed MS over 15 years. Among those with one or more lesions, about 72% did. Overall, the figure was about 50%. Notably, among patients with a normal MRI, certain features — male sex, marked optic disc swelling, and the absence of pain — were associated with a lower risk.
Section 03 — Symptoms & Red Flags
Typical optic neuritis
has a recognisable pattern.
Most of the diagnosis is clinical. The pattern — young adult, one eye, pain on movement, dimming over days, then recovery — is distinctive enough that departures from it matter more than any single test.
| Feature | Typical (demyelinating) | Suggests atypical cause |
|---|---|---|
| Pain | Pain on eye movement, usually mild to moderate | No pain at all, or severe pain disturbing sleep |
| Eyes affected | One eye | Both eyes at once, or in rapid sequence |
| Severity | Blur to moderate loss; colours washed out | Profound loss, e.g. no light perception |
| Optic disc | Normal or mildly swollen | Marked swelling, haemorrhages or exudates |
| Recovery | Begins within about 3 weeks | No improvement by 3–4 weeks, or worsening after steroids stop |
| Age | Roughly 20–45 | Over 50 (consider ischaemic optic neuropathy, giant cell arteritis) or child |
Other common complaints are a dark or grey patch in central vision, colours (particularly red) looking faded in the affected eye, and reduced brightness. Some people notice vision temporarily worsens with heat, a hot shower or exercise — Uhthoff phenomenon, caused by heat further slowing conduction in damaged fibres. It is a sign of past demyelination, not a new attack.
Section 04 — Diagnosis
Four tests that
confirm the nerve is the source.
An eye specialist is usually looking for evidence that the problem lies in the optic nerve rather than the retina, then for clues about the cause.
Section 05 — The Evidence
What the Optic Neuritis
Treatment Trial actually showed.
The ONTT, published in the New England Journal of Medicine in 1992, randomised 457 patients to one of three arms: high-dose intravenous methylprednisolone followed by oral prednisone, oral prednisone alone at standard dose, or placebo. Its findings still shape practice.
Published ONTT figures, rounded (Beck et al. 1992; Optic Neuritis Study Group 2008). See References.
Three conclusions came out of the trial. First, intravenous methylprednisolone made vision recover faster, but by six months to a year, final visual outcomes were essentially the same as placebo. Second, oral prednisone alone at the standard dose gave no benefit and was associated with a higher rate of new optic neuritis episodes — so it is not used on its own for typical optic neuritis. Third, the vast majority of patients recovered good vision regardless of treatment arm, confirming that typical optic neuritis has a favourable natural course.
A companion analysis (Beck et al., 1993) suggested IV treatment was associated with a lower rate of MS over the first two years, but that effect did not persist on longer follow-up. Today, IV steroids are generally offered when faster recovery matters to the patient — for example, if the other eye already has poor vision — rather than to change the long-term outcome.
in the ONTT
prednisone, placebo
follow-up
Section 06 — Not All Optic Neuritis Is the Same
MS, NMOSD, MOG:
three diseases,
three different plans.
Since the ONTT, two antibody-defined conditions have been separated out. They can begin exactly like typical optic neuritis, but they behave differently and are treated differently, which is why antibody testing matters when anything looks atypical.
| Feature | MS-associated | NMOSD (AQP4-IgG) | MOG antibody disease |
|---|---|---|---|
| Severity | Mild to moderate | Often severe | Often severe at onset |
| Recovery | Usually good | Often incomplete | Usually good, but relapses common |
| Disc swelling | Usually absent or mild | Variable | Often marked |
| Both eyes | Uncommon | Can occur | Relatively common |
| Acute approach | Observation or IV steroids | Urgent high-dose steroids; plasma exchange often used | High-dose steroids, often a slower taper |
The practical point: some MS disease-modifying drugs can worsen NMOSD, so getting the diagnosis right matters for long-term treatment as well as the acute attack. The 2015 international consensus criteria for NMOSD (Wingerchuk et al.) and more recent optic neuritis classification work (Petzold et al., 2022) both emphasise early antibody testing in atypical presentations.
Section 07 — Putting It Together
A typical first attack,
start to finish.
Over four days, a woman notices a grey smudge in the centre of her right eye's vision, reds look faded, and the eye aches when she looks to the side. Examination finds reduced acuity, a right relative afferent pupillary defect and a normal-looking optic disc. Orbit MRI shows an enhancing right optic nerve; brain MRI shows two small white-matter lesions.
This is a typical presentation. She is offered, and declines, IV steroids after hearing they would speed recovery without changing the final result. Vision starts improving in the third week and is near normal by three months, though colours in that eye remain slightly duller. Because of the brain lesions, she is referred to neurology to discuss her MS risk and whether early disease-modifying treatment is appropriate.
Long-term, OCT often shows some thinning of the retinal nerve-fibre layer in the affected eye even when vision feels normal, a structural footprint of the attack. That thinning is one reason OCT has become a useful tool in MS clinics as well as eye clinics.
Section 08 — FAQ
Frequently asked questions
about optic neuritis.
Optic neuritis is inflammation of the optic nerve, the cable that carries visual signals from the eye to the brain. The inflammation strips or disrupts the myelin insulation around nerve fibres, so signals travel slowly or fail. It typically causes blurred or dim vision in one eye over a few days, washed-out colours, and pain when the eye moves. It is most common in adults aged roughly 20 to 45, and more common in women.
Pain on eye movement is the hallmark symptom. In the Optic Neuritis Treatment Trial, about 92% of patients reported eye pain, usually worse with movement. The likely reason is that the inflamed optic nerve sheath sits close to where several eye muscles attach at the back of the orbit, so every eye movement tugs on inflamed tissue. Painless optic nerve vision loss, especially in someone over 50, points toward other causes such as ischaemic optic neuropathy and needs a different work-up.
In typical demyelinating optic neuritis, most people recover a large share of their vision, usually starting within a few weeks and continuing over months. Most patients in the Optic Neuritis Treatment Trial recovered to good acuity. Recovery is often not perfect: subtle loss of contrast, colour saturation or brightness can persist, and vision may dim temporarily with heat or exercise (Uhthoff phenomenon). Failure to start improving within about three weeks is a red flag for an atypical cause.
Not necessarily, but it is linked. In the Optic Neuritis Treatment Trial's 15-year follow-up, the overall risk of developing MS was about 50%. The strongest predictor was the brain MRI at presentation: about 25% of patients with no brain lesions developed MS, versus about 72% of those with one or more lesions. This is why a brain MRI with contrast is a standard part of the work-up.
The Optic Neuritis Treatment Trial found that high-dose intravenous methylprednisolone followed by oral prednisone sped up visual recovery but did not change final vision at one year compared with placebo. Standard-dose oral prednisone alone did not help and was associated with a higher rate of new optic neuritis episodes, so it is not used on its own. Whether to give IV steroids is an individual decision made with a neuro-ophthalmologist or neurologist. Atypical forms (NMOSD, MOG antibody disease) are treated more urgently and differently.
They are antibody-mediated conditions that can look like typical optic neuritis but behave differently. Neuromyelitis optica spectrum disorder (NMOSD), usually with aquaporin-4 antibodies, tends to cause more severe vision loss, poorer recovery and attacks of the spinal cord. MOG antibody-associated disease often causes marked optic disc swelling, can affect both eyes, and tends to respond strongly to steroids but may relapse. Severe loss, both eyes affected, poor recovery or marked disc swelling should prompt blood tests for these antibodies.
References & Evidence Base
Peer-reviewed
citations.
Continue Reading
Related guides
from Beyond Vision.
Start writing here...
Optic Neuritis: Painful Vision Loss, the MS Link & What the Steroid Trial Showed (2026 Guide)